蛋白酶体作为治疗寄生虫病的药物靶点。

3区医学 Q1 Immunology and Microbiology

Advances in Parasitology Pub Date : 2024-01-01 Epub Date: 2024-09-23 DOI:10.1016/bs.apar.2024.04.001

Lawrence J Liu, Anthony J O'Donoghue, Conor R Caffrey

{"title":"蛋白酶体作为治疗寄生虫病的药物靶点。","authors":"Lawrence J Liu, Anthony J O'Donoghue, Conor R Caffrey","doi":"10.1016/bs.apar.2024.04.001","DOIUrl":null,"url":null,"abstract":"The proteasome is a proteolytically active molecular machine comprising many different protein subunits. It is essential for growth and survival in eukaryotic cells and has long been considered a drug target. Here, we summarize the biology of the proteasome, the early research relating to the development of specific proteasome inhibitors (PIs) for treatment of various cancers, and their translation and eventual evolution as exciting therapies for parasitic diseases. We also highlight the development and adaptation of technologies that have allowed for a deep understanding of the idiosyncrasies of individual parasite proteasomes, as well as the preclinical and clinical advancement of PIs with remarkable therapeutic indices.","PeriodicalId":50854,"journal":{"name":"Advances in Parasitology","volume":"126 ","pages":"53-96"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The proteasome as a drug target for treatment of parasitic diseases.\",\"authors\":\"Lawrence J Liu, Anthony J O'Donoghue, Conor R Caffrey\",\"doi\":\"10.1016/bs.apar.2024.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The proteasome is a proteolytically active molecular machine comprising many different protein subunits. It is essential for growth and survival in eukaryotic cells and has long been considered a drug target. Here, we summarize the biology of the proteasome, the early research relating to the development of specific proteasome inhibitors (PIs) for treatment of various cancers, and their translation and eventual evolution as exciting therapies for parasitic diseases. We also highlight the development and adaptation of technologies that have allowed for a deep understanding of the idiosyncrasies of individual parasite proteasomes, as well as the preclinical and clinical advancement of PIs with remarkable therapeutic indices.\",\"PeriodicalId\":50854,\"journal\":{\"name\":\"Advances in Parasitology\",\"volume\":\"126 \",\"pages\":\"53-96\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Parasitology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.apar.2024.04.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Parasitology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.apar.2024.04.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

摘要

蛋白酶体是一种具有蛋白水解活性的分子机器，由许多不同的蛋白质亚基组成。它对真核细胞的生长和存活至关重要，长期以来一直被视为药物靶标。在此，我们总结了蛋白酶体的生物学特性、与开发用于治疗各种癌症的特异性蛋白酶体抑制剂（PIs）有关的早期研究，以及它们作为治疗寄生虫病的令人兴奋的疗法的转化和最终演变。我们还重点介绍了技术的发展和调整，这些技术使我们能够深入了解寄生虫蛋白酶体的特异性，以及具有显著治疗指数的蛋白酶体抑制剂的临床前和临床进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The proteasome as a drug target for treatment of parasitic diseases.

The proteasome is a proteolytically active molecular machine comprising many different protein subunits. It is essential for growth and survival in eukaryotic cells and has long been considered a drug target. Here, we summarize the biology of the proteasome, the early research relating to the development of specific proteasome inhibitors (PIs) for treatment of various cancers, and their translation and eventual evolution as exciting therapies for parasitic diseases. We also highlight the development and adaptation of technologies that have allowed for a deep understanding of the idiosyncrasies of individual parasite proteasomes, as well as the preclinical and clinical advancement of PIs with remarkable therapeutic indices.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Parasitology 医学-寄生虫学

CiteScore

9.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Advances in Parasitology is recognised as a leading review serial which is consistently well placed in terms of impact factor and citations. Major reviews on all aspects of medical, veterinary and wild-life parasitology are considered. The journal provides an outlet for authoritative reviews from experts in the field. While emphasis is given to modern molecular approaches contributions across all disciplines are encouraged including traditional areas such as ecology and taxonomy. Eclectic volumes are supplemented by thematic volumes dedicated to a particular topic of recognised interest and importance.